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Abstract 
Purpose: The aim of this study was to determine the in vitro effectiveness of Plantago major 
extract, along with two of its active components, aucubin and baicalein, on the inhibition of 
Candida albicans growth, biofilm formation, metabolic activity and cell surface hydrophobicity. 
Materials and Methods: Two-fold dilutions of Plantago major, aucubin and baicalein were used 
to determine the minimum inhibitory concentration (MIC), minimum fungicidal concentration 
(MFC), and the minimum biofilm inhibitory concentration (MBIC) of each solution. Separately, 
two-fold dilutions of Plantago major, aucubin and baicalein were utilized to determine the 
metabolic activity of established C. albicans biofilm using a 2,3-bis (2- methoxy-4-nitro-5-
sulfophenyl)-2H-tetrazolium-carboxanilide reduction assay. Two-fold dilutions of Plantago 
major, aucubin and baicalein were used to determine the cell surface hydrophobicity of treated C. 
albicans biofilm by a two-phase assay using hexadecane. The hydrophobicity percentage of the 
cell surface was then calculated.  A mixed-model ANOVA test was used for intergroup 
comparisons.  
Results: The MIC’s of P. major extract (diluted 1:2-1:8), aucubin (61-244 µg/ml) and baicalein 
(0.0063-100 µg/ml) on the total growth of C. albicans were noticeable at their highest 
concentrations, and the inhibition was dose-dependent. The MFC was evaluated after 48 h of 
incubation and aucubin (244 µg/ml) exhibited a strong fungicidal activity at its highest 
concentration against C. albicans growth. The MBIC indicated no growth or reduced growth of C. 
albicans biofilm at the highest concentrations of aucubin (61-244 µg/ml) and baicalein (25-100 
µg/ml). Similarly, the effects of these reagents on C. albicans biofilm metabolic activity and 
hydrophobicity demonstrated high effectiveness at their highest concentrations.  
Conclusion: P. major extract, aucubin and baicalein caused a dose-dependent reduction on the 
total growth, biofilm formation, metabolic activity and cell surface hydrophobicity of C. albicans.
This demonstrates their effectiveness as anti-fungals and suggests their promising potential use as 
solutions for C. albicans biofilm related infections. 
Keywords:; Candidiasis; anti-fungal; denture stomatitis; biofilm; crystal violet; hexadecane.
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1. Introduction 
Candida albicans is a dimorphic fungus that can be either a commensal or an opportunistic 
pathogen with the ability to cause a variety of infections in the oral cavity as well as other parts of 
the human body.1-4 Opportunistic fungal pathogens are often responsible for common superficial 
infections, but sometimes are the cause of life threatening deep – seated mycoses.5  C. albicans is 
not only capable of invading and forming biofilm on virtually every site on the human body, but 
can also attach to biomaterials.2,4 There is an increased prevalence of Candida infections 
worldwide that are difficult to treat such as invasive candidiasis. 4 
Oral candidiasis is the collective term for a number of distinct clinical pathologies caused 
by Candida species, predominantly C. albicans. Oral lesions of Candida origin are categorized as: 
pseudomembranous candidiasis (oral thrush), erythematous candidiasis (atrophic) and 
hyperplastic candidiasis (Candida leukoplakia).3,6 Many factors can predispose individuals to 
candidiasis. Some are mechanical such as ill-fitting dentures, some are short-term such as a course 
of antibiotic therapy, and some are associated with simply old age. Additionally, recent studies 
have found that certain type of proteins in saliva may predispose some patients to dentures 
stomatitis, causing disease from non-fungal relation.7 Other types of predisposing factors are 
related to underlying diseases such as immunosuppressive therapy, HIV-infection and diabetes 
mellitus.2,6,8   
The most common clinical manifestation of oral candidiasis is denture stomatitis. 2,6,9 It 
occurs in up to 67% of denture wearers and its multifactorial etiology makes it difficult to treat.2,4,7 
Increased colonization of C. albicans, and other types of candida species like C. glabrata seem to 
be involved in the development of denture stomatitis even when the normal bacterial flora seems 
not to be greatly altered.6,7,9 This is supported by several studies, which describe the entrapment 
of yeast cells in irregularities of denture-base and denture-relining materials, that could serve as a 
reservoir of microorganisms.4,10,11 Hence the recurrence of stomatitis is very likely to occur after 
anti-fungal therapy is discontinued. Anti-fungal agents commonly used to treat oral candidiasis 
patients are of a wide spectrum and if indiscriminately used can cause undesirable side-effects and 
permit the emergence of resistant organisms. This leads to the need to find effective natural 
solutions capable to inhibit the growth and biofilm formation of Candida related fungus not only 
at tissue level but also in biomaterials such as dentures.     
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The pathogenesis of Candida infections is complex, involving yeast and host-factors. The 
ability of Candida strains to overcome host clearance mechanisms and colonize surfaces depends 
on the effectiveness of the yeast mechanisms, its capability of adherence, and its growth rate.11 
According to Pereira-Censi et al.4 many studies have demonstrated the adhesion of C. albicans to 
denture surfaces and they proposed that the more hydrophobic the surface, the more cell adherence. 
In other words, the higher the surface free energy, the higher will be the adhesion of the 
microorganisms. Furthermore, there seems to be a close relationship between the adherence of C. 
albicans to plastic surfaces and yeast cell surface hydrophobicity (CSH). This interaction is 
essential for initial resistance or adherence of yeast to acrylic surfaces, because the more 
hydrophobic the microorganism, the more adherent the microbes are to surfaces that are likewise 
hydrophobic.13-14 Adhesion often leads to colonization and subsequently induces pathology.4 
Should adherence occur, there is greater opportunity for further Candida binding and in cases of 
denture stomatitis further formation of “denture plaque”.1 Irreversible adhesion to host tissues and 
prostheses often leads to biofilm formation.5  
Biofilm is defined as a surface-associated, highly structured community of microorganisms 
that is enclosed by self-production of a protective extracellular matrix called extracellular 
polymeric substance (EPS).15 These oriented aggregations of microorganisms attach to one another 
on living or non-living surfaces, and being embedded within EPS helps maintain biofilm 
structures.16 In contrast to planktonic cells, biofilm cells display unique phenotypic traits, the most 
outstanding of which is their notorious resistance to both anti-fungal agents and to host immune 
factors.8 Biofilm-associated Candida infections are difficult to treat and are a danger to patients.5 
The limitations and restricted target range of current anti-fungal medications, have led to a search 
for more effective anti-fungal treatments.6  In order to reduce further development of anti-fungal 
medication resistance, there is a need to identify new methods of preventing and treating 
candidiasis. For this reason, new therapeutic strategies using medicinal plants and their 
components would be of significant importance as alternatives in the prevention and management 
of C. albicans biofilm formation. 
P. major is a perennial herb that belongs to the family of Plantaginaceae.17 It originated in 
Europe and Asia. In English it is known as greater Plantain, in French it is known as Plantain, in 
Portuguese as Tranchagem, and in Spanish as Llantén.12,18 It is well known for its wound healing, 
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oral wound healing, analgesic, anti-inflammatory, anti-oxidant, anti-viral, and anti-fungal 
properties.12,19 It contains five classes of eleven biologically active compounds: benzoic compound 
(vanillic acid), flavonoids (baicalein, baicalin, luteolin), iridoid glycoside (aucubin), phenolic 
compounds (caffeic acid, chlorogenic acid, ferulic acid, p-coumaric acid) and triterpenes 
(oleanolic acid, ursolic acid).20 Many of P. major’s medicinal properties may be attributed to two 
of its biologically active components, aucubin (AU) and baicalein (BE). 
AU can be isolated from the leaves of P. major, P. asiatica and Eucommia ulmoides.20-22 
It has numerous pharmacological effects such as being anti-microbial, anti-inflammatory, 
hepatoprotective, choleretic, hemodynamic, anti-spasmodic, anti-nociceptive, and inhibition of 
RNA and protein biosynthesis in sarcoma 180 cells, and promoter of dermal wound healing.21-23 
Additionally, Shim et al.21 concluded in his study that AU is useful for oral wound healing due to 
its anti-inflammatory effect and that it may be applied as a topical agent to oral wounds. Similarly, 
Kang et al.23 recommended that AU be further researched and utilized due to its extensive 
pharmacological properties. 
BE can be isolated from P. major and the traditional Chinese medicinal plant Scutellaria 
baicalensis Giorgi.20,24 Several pharmacological studies of BE have demonstrated its anti-
oxidative, anti-microbial and neuro-protective effects.8 Other studies have demonstrated BE has 
anti-inflammatory and anti-cancer effects.20,25 With respect to its anti-fungal aspect, BE has been 
found to inhibit C. albicans growth and its biofilm formation.8,26  Additional studies have found 
that BE also exhibits an in vitro synergism with fluconazole on C. albicans.27,28 Kang et al. 29 found 
in his study that BE could not induce apoptosis in C. albicans and suggested that BE affected 
fungal growth via different pathways.   
To date, only a few studies have investigated the role of P. major extract, AU and BE as 
anti-fungal agents against C. albicans growth, biofilm formation, metabolic activity and 
hydrophobicity. Therefore, it would be of significant advantage to find new prospective natural 
resources to eradicate C. albicans biofilm related infections. The aim of this study was to assess 
the in vitro effects of P. major extract, along with two of its active components, (AU and BE), on 
the inhibition of C. albicans growth, biofilm formation, metabolic activity and cell surface 
hydrophobicity. The hypothesis was that P. major extract, AU and BE will cause dose-dependent 
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reductions on C. albicans growth, biofilm formation, metabolic activity and cell surface 
hydrophobicity, when compared to the negative control group. 
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2. Materials and Methods 
2.1 Fungal Strain, Growth Medium and Anti-fungal Agents 
C. albicans was obtained from the American Type Culture Collection (ATCC). C. albicans ATCC 
10231 was chosen because is a widely used clinical isolate in many C. albicans studies. The strain 
was originally isolated from a patient with bronchomycosis.30 Stock cultures were stored at -80°C, 
passaged onto a blood agar plate and incubated in 95% O2/5% CO2 at 37°C prior to use. C. albicans 
cells were inoculated into 5 ml of yeast-peptone-dextrose (YPD) broth medium (1% w/v yeast 
extract, 2% w/v peptone, 2% w/v dextrose; Fisher Scientific, Newark, DE, USA).  Thereafter, 
batches of inocula were incubated overnight in an orbital shaker (120-150 r.p.m) at 30°C.1,5,8,12,15,22  
C. albicans grew in the budding-yeast phase under these conditions.2,15 
P. major extract was purchased in 30X potency containing 20% alcohol (Washington 
Homeopathic Products, Berkeley Spring, WV).31 P. major extract was diluted with YPD media by 
two-fold dilutions up to 1:512. This potency of P. major extract contains 0.05 µg/ml of AU and 
0.0425 µg/ml of BE.20 (Table 1) 
AU and BE were obtained from Sigma-Aldrich, St Louis, MO. Both components were 
dissolved in concentrations ranging from 0-244 µg/ml-1 in dimethyl sulfoxide (DMSO) and stored 
at –20°C.8,20 The final concentration of DMSO used alone in all assays was not inhibitory towards 
C. albicans in agar diffusion assays (data not shown).  
 
2.2 Minimum Inhibitory Concentration and Minimum Fungicidal Concentration 
The minimum inhibitory concentration (MIC) is the lowest concentration of an agent that inhibits 
the visible growth of a microorganism, and the minimum fungicidal concentration (MFC) is the 
lowest concentration of the agent that kills the fungus.32 The MIC of P. major extract, AU and BE 
against C. albicans were determined by two-fold dilutions with YPD media in sterile 96-well flat-
bottom microtiter plates (MTP) (Fisher Scientific, Newark, DE, USA). P. major extract 30X in 
1:2n nine dilutions, AU concentrations ranging from 0.96-244 µg/ml and BE from 0.006-100 µg/ml 
in YPD (190 µl) were added to 96-well MTP with 10 µl of an overnight culture of C. albicans and 
incubated for 24 h or 48 h at 37°C. The total yeast growth in the presence of the agents was 
estimated using a microtiter plate reader (Spectra Max 190; Molecular Devices, Sunnyvale, CA, 
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USA) at a wavelength of 595 nm after incubation. The MIC was determined as the lowest 
concentration of the reagents that yielded a change in OD from the control of ≥0.050. The negative 
control group was YPD inoculated with C. albicans. 
To determine the MFC, 10 µl from the 96-well MTP with reagent concentrations equal to 
or higher than the MIC were transferred onto blood agar plates (Fisher Scientific) and incubated 
in 95% O2/5% CO2 at 37°C. The MFC was defined as the lowest concentration of the reagents that 
had no visible yeast colonies on the agar plates after 48 h of incubation.   
 
2.3 Minimum Biofilm Inhibitory Concentration  
The minimum biofilm inhibitory concentration (MBIC) is the lowest concentration of an agent 
that inhibits the visible biofilm formation of a microorganism.32 The MBIC was determined by the 
same two-fold dilution of P. major extract, AU and BE. The same 96-well MTP was used after the 
MIC was determined.  The planktonic culture fluid was gently shaken out, fixed with 200 µl of 
10% formaldehyde for 30 min, and stained with 200 µl of 0.3% crystal violet for 30 min. After 
washing the biofilm twice with sterile water, crystal violet was extracted from the biofilm cells by 
incubation of 200 µl of 2-propanol for 1 h. The absorbance was read at 490 nm. The control group 
was YPD inoculated with C. albicans.  
  
2.4 Biofilm Metabolic Activity 
The metabolic activity of C. albicans was measured using a method described by Pierce et al.15 
This technique requires 24 h established C. albicans biofilms on the bottom of the 96-well MTP, 
coupled with a colorimetric method that measures the metabolic activities of biofilm cells based 
on the reduction of 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-carboxanilide 
(XTT; Sigma). Upon processing by metabolically active cells, XTT yields a water-soluble 
formazan-colored product that is measured in a spectrophotometer. The XTT-reduction assay 
indicates an excellent correlation between cellular density and metabolic activity, thus providing 
a semi-quantitative measurement of biofilm formation. This colorimetric assay is noninvasive and 
nondestructive, requiring minimal post-processing samples. Furthermore, this correlates with cell 
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viability, which is particularly useful for measuring the effects of anti-fungal agents on biofilm 
cells.2,15,33   
The 96-well MTP were seeded for 24 h with 10 µl of an C. albicans overnight culture in 
190 µl of YPD without the reagents to allow biofilm to grow, followed by another 24 h of growth 
in YPD supplemented with two-fold dilutions of P. major extract, AU and BE. C. albicans 
planktonic cells in the 96-well MTP were gently shaken out and 200 µl of XTT/menadione reagent 
added.2,17 The plates were kept in the dark for 2 h at 37°C in an atmosphere of 95% O2/5% CO2.  
After incubation, 120 µl of the solution was transferred to a blank MTP and any color change was 
detected by measuring the absorbance at 490 nm in a spectrophotometer.  The negative control 
group was YPD inoculated with C. albicans.  
 
2.5 Cell Surface Hydrophobicity Assay 
The cell surface hydrophobicity (CSH) of C. albicans was determined by measuring the yeast 
adherence to a water-hydrocarbon two-phase assay using hexadecane.14 Two-fold dilutions of P. 
major extract, AU and BE in YPD (3 ml) were added to six-well tissue culture plates with 150 µl 
of an overnight inoculum of C. albicans and incubated for 24 h at 37°C. Briefly, biofilm cells were 
scraped off the bottom of the culture plates and suspended in 1.5 ml of YPD to yield an optical 
density of approximately 1.0 at 620 nm. From this cell suspension, 1.3 ml was pipetted into 
borosilicate glass tubes (18 mm × 75 mm). From each tube, 100 µl of the cell suspensions were 
pipetted into wells of a 96-well MTP. The plate was read at 620 nm and designated as the initial 
OD of the cell suspension. The 1.2 ml of cell suspension remaining in the glass tubes was overlaid 
with 0.3 ml of hexadecane. The phases were vigorously mixed and vortexed for 3 min and allowed 
to separate for 15 min. The lower aqueous phase was carefully withdrawn with a pipette and 100 
µl was added to each microtiter well. The absorbance was read and noted as the final OD of the 
aqueous phase. Tubes without the reagents served as the control group. The percentage 
hydrophobicity of the yeast cell surface was calculated by the following formula: %CSH = (1-final 
OD of aqueous phase/initial OD of cell suspension) × 100.5,10  
 
2.6 Statistical Analysis 
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The different experiments were compared for differences in total growth, biofilm formation, 
biofilm metabolic activity, and cell surface hydrophobicity using a mixed-ANOVA. The ANOVA 
included a fixed effect for the 1:2n nine dilutions of the P. major extract, AU and BE, and a random 
effect for the experiment. Fisher’s Protected Least Significant Differences was used to control the 
overall significance level at 5%. Distribution of the data was examined and a transformation of the 
data was used. 
With a sample size of 144 two-fold dilutions for each reagent for each of 4 experiments, 
the study had 80% power to detect differences between groups of 0.05 for total growth, biofilm 
formation and cell surface hydrophobicity and differences between groups of 0.025 for biofilm 
metabolic activity. The calculations assumed two-sided tests each conducted at a 5% significance 
level and within-group standard deviations of 0.05 for biofilm formation,32 biofilm metabolic 
activity,10 and cell surface hydrophobicity.8 All data were expressed as mean values with the 
corresponding standard deviations.  
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3.  Results 
P. major extract (diluted 1:2-1:8), AU (61-244 µg/ml) and BE (0.0063-100 µg/ml) demonstrated 
clear inhibition against C. albicans growth (Fig. 1). These differences were statistically significant 
(p < 0.0001). The data also indicated BE was more effective at lower concentrations (≥ 0.0063 
µg/ml) than P. major and AU. 
The MFC, after 48 h of incubation, indicated that AU has a noticeable fungicidal activity 
against C. albicans growth at its highest concentration of 244 µg/ml (Table 2). In contrast, P. major 
extract and BE demonstrated some fungicidal activity against C. albicans but this was not 
significant.  
AU (61-244 µg/ml) and BE (25-100 µg/ml) revealed a significant dose-dependent 
reduction against C. albicans biofilm formation when compared to the negative control group (p 
< 0.0001; Fig. 2). Lower concentrations of aucubin (1-31 µg/ml) and baicalein (0.4-12.5 µg/ml) 
also produced some effect on C. albicans biofilm formation, but this was not statistically 
significant as well as all the concentrations of P. major extract. 
To provide a more quantitative assessment of cellular activity of established C. albicans 
biofilm in the presence or absence of the reagents, the ability of the yeast to reduce XTT was 
measured (Fig. 3). The inhibitory effects of C. albicans metabolic activity were limited to P. major 
extract (diluted 1:2; p < 0.0159) and AU (244 µg/ml; p < 0.0001). Clearly the inhibition was dose-
dependent only at the highest concentrations of these two reagents and was statistically significant. 
The results also demonstrated that the inhibitory effects were active on C. albicans that had already 
grown in an established biofilm, which usually are the most problematic to treat. On the other 
hand, BE demonstrated no inhibition on the metabolic activity of C. albicans.  
To examine the effect of P. major, AU and BE on the yeast adherence mechanism, the cell 
surface hydrophobicity of treated C. albicans biofilm was measured by a two-phase separation 
method using hexadecane (Fig. 4). The water-hydrocarbon two-phase assay demonstrated a 
decrease in hydrophobicity of C. albicans biofilm at only the highest concentrations of AU (244 
µg/ml; p < 0.0048) and BE (100 µg/ml; p < 0.0375) when compared to their control group.  
However, P. major extract had little effect on the CSH of the yeast.  
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4.  Discussion 
Biofilm associated Candida infections are a danger to patients and are challenging to treat 
because of the complex pathogenesis that involves not only the yeast but host factors as well.1,17  
The present study demonstrated that the P. major extract, aucubin and baicalein effectively 
inhibited C. albicans growth, while the active components of the plant (AU and BE) at higher 
concentrations, exerted strong inhibitory effects against C. albicans biofilm formation and 
additionally displayed strong fungicidal activity against the yeast. These results are in agreement 
with earlier data that depicted the usefulness of the reagents in having antimicrobial 
activities.8,12,17,19,21-23,27-29,34 Ever since ancient times, people have looked to nature for cures. Plants 
have been used because of their effectiveness, low cost, and accessibility. Medicinal plants are a 
valuable natural resource due to their antimicrobial activities. Their side effects are often less 
severe than synthetic medications.12,34 They play a principal role in the health care systems of rural 
and remote communities where the population depends on folklore and herbal medicines. P. major 
is an herb that has been used worldwide for hundreds of years for its medicinal properties. This 
natural resource would potentially benefit the oral health of at risk populations, such as denture 
wearers, debilitated elderly, immunocompromised individuals like neonates and other populations 
with fungal infections caused by C. albicans.  
Appropriate further studies will be necessary to investigate alternative medical uses of the 
plant extract and components for their routes of administration such as, and not limited to, mouth 
rinses, troches, creams, ointments and/or in combination with existing anti-fungal agents. Topical 
application of the reagents would be rather safe and their cytotoxicity should not be a deterrent as 
this is supported by the study of Reina et al.20 that concluded that P. major and BE were not 
cytotoxic at any of the concentrations examined, and AU was cytotoxic only at the concentration 
of 100 µg/ml, when studied on human neutrophils. Even though in the present study AU (244 
µg/ml) at a higher concentration had an effect on C. albicans viability, a medication such as a 
mouthwash containing this solution would not have much potential of toxicity in the oral cavity 
tissues and other tissues not in direct exposure to neutrophils.  
Furthermore, in accordance with Shim et al.21 AU was suggested as a potentially safe drug 
to use in the oral cavity. Most importantly, it should be taken into consideration that the reduction 
in C. albicans viability and biofilm formation obtained from treatment with P. major, AU and BE 
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at lower concentrations may be sufficient for the subject’s immune system to completely eradicate 
C. albicans related infections. 
The ability of these three agents to inhibit C. albicans biofilm formation was dose-
dependent to their concentrations. Other studies8,27-29 have also supported this dose-dependent 
relation to the inhibition of C. albicans biofilm formation. Additionally, it was found that AU was 
the most effective in the decrease of C. albicans biofilm formation and the only agent to maintain 
the inhibition of viability of the yeast for over 48 hours. 
The metabolic activity of C. albicans biofilm formation was assessed using XTT-reduction 
of tetrezolium to a tetrazolium formazan product by mitochondrial-active C. albicans in the 
presence of menadione.29 The correlation between cellular density and metabolic activity provides 
an excellent semi-quantitative measurement of biofilm formation.15 The colorimetric assay is 
noninvasive and nondestructive, requiring minimal post-processing sampling. This also correlated 
with cell viability, which is particularly useful for measuring the effects of anti-fungal agents on 
biofilm cells.2,15 Among the three reagents, AU (244 µg/ml) and the P. major extract (diluted 1:2) 
exerted an effect towards C. albicans established biofilm metabolic activity. However, BE did not 
exhibit inhibition of the metabolic activity of C. albicans biofilm at any of its concentrations. This 
correlates with the data from Kang et al.29 who demonstrated that BE could not induce apoptosis 
in C. albicans yet affected fungal growth via a different pathway. The results in this study indicated 
that BE affected C. albicans biofilm formation via cell surface hydrophobicity and in correlation 
with the findings of Cao et al.8 BE affects the growth surface of C. albicans composition from true 
hyphae to yeast cell and pseudo-hyphae after treatment. P. major extract and AU behaved similarly 
to BE at their highest concentrations, and based on the growth inhibitory effects they contributed 
to poor biofilm formation. This, therefore, suggests their effectiveness in preventing C. albicans 
colonization and more importantly in preventing biofilm from becoming resistant.  
The resistance of biofilm is likely multifactorial and among many mechanisms it may be 
due to the yeast cell surface hydrophobicity (CSH). CSH is important for the regulation of the 
pathogenicity of C. albicans biofilm, since elevated CSH causes increased adhesion of the 
organism to tissue surfaces and acrylic surfaces. Many studies have demonstrated that the more 
hydrophobic the microorganism the more adherent the cells are to acrylic surfaces. Furthermore, 
other studies have shown that C. albicans are less hydrophobic when compared to C. tropicallis 
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and relatively hydrophilic when compared to C. glabrata. 4,11 Raut et al.5 stated that C. albicans is 
known to regulate cell surface hydrophobicity status according to growth phase, environment and 
nutritional conditions, making this mechanism difficult to study. In the present study, decreased 
CSH was observed at the highest concentrations of AU (244 µg/ml) and BE (100 µg/ml), where 
the increased effects of biofilm inhibition was noted. This negative correlation was similarly 
described by Cao et al.8  
Further investigations to examine the role of P. major extract, AU and BE in acrylic and 
nylon denture base materials and their role in the inhibition of C. albicans biofilm formation are 
needed. Also, further studies may test the agents’ solution in human affected tissues and their 
effectiveness against the growth of other non-albicans Candida species. Kang et al.23 suggested 
that AU be further researched and utilized as a feasible anti-fungal medication, and in accordance 
with this study AU has the potential to be used as anti-fungal rinse against the growth of C. 
albicans due to its outstanding shown fungicidal properties. 
Several other biologically active components of P. major extract should also be taken in 
consideration because it was shown that AU and BE at concentrations within the plant had little 
or no inhibitory effect against C. albicans biofilm formation when tested individually. However, 
those same concentrations, within the plant extract, displayed inhibition against C. albicans growth 
and metabolic activity, therefore, our findings show that P. major benefits from its anti-fungal 
properties from a combination of the plants eleven biologically active components working 
together, giving the plant its medicinal properties. 
 
 
5. Conclusion 
Within the limitations of this study the following conclusions can be drawn: 
1. Collectively, P. major extract, and AU and BE demonstrated anti-fungal activity against 
C. albicans total growth. 
2. P. major extract demonstrated weak inhibition of C. albicans biofilm formation and 
viability when compared to its components (AU and BE) in higher concentrations.  
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3. AU exhibited strong anti-fungal activity against C. albicans growth, biofilm formation, 
biofilm metabolic activity and CSH and was the only agent that provided continuous 
fungicidal activity against C. albicans viability. 
4. BE revealed strong inhibition of C. albicans growth and its biofilm formation by inhibiting 
the cell surface hydrophobicity pathway. 
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Table 1: Aucubin and baicalein concentrations in Plantago major extract 30X19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: The anti-fungal effects on Candida albicans viability of Plantago major, aucubin and 
baicalein (MFC)  
Dil. of 
P. 
major  
1:2 1:4 1:8 1:16 1:32 1:64 1:128 1:256 1:512 
Aucubin 
(µg/ml) 
0.25 0.125 0.062 0.031 0.015 0.0078 0.0039 0.0019 0.0009 
Baicalein 
(µg/ml) 
0.212 1.106 0.053 0.026 0.013 0.0066 0.0033 0.0016 0.00083 
  
19 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anti-Fungal Reagents 
 
Minimum Fungicidal 
Concentration (MFC) 
Plantago major extract 
 
 ˃ 60X  
Aucubin  244 µg/ml 
Baicalein  ˃ 100 µg/ml 
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Legends 
Figure 1 MIC’s of (A) Plantago major extract, (B) aucubin and (C) baicalein on the total growth 
of C. albicans after 24-48 h at 37 °C. The data are expressed as mean absorbance (595 nm) ± 
S.E.M * P < 0.05, ** P < 0.01 when compared with the respective control groups. 
Figure 2 MBIC’s of (A) Plantago major extract, (B) aucubin and (C) baicalein on C. albicans 
biofilm formation after 24-48 h at 37 °C. The data are expressed as mean absorbance (490 nm) ± 
S.E.M * P < 0.05, ** P < 0.01 when compared with the respective control groups.  
Figure 3 The biofilm metabolic activity of (A) Plantago major extract, (B) aucubin and (C) 
baicalein on established C. albicans biofilm formation after 48 h at 37 °C. The data are expressed 
as mean absorbance (490 nm) ± S.E.M * P < 0.05, ** P < 0.01 when compared with the respective 
control groups.  
Figure 4 The cell surface hydrophobicity of (A) Plantago major extract, (B) aucubin and (C) 
baicalein on C. albicans biofilm after 48 h at 37 °C. The relative hydrophobicity of the control 
group was set at 1.0. The data are expressed as mean relative hydrophobicity ± S.E.M * P < 0.05, 
** P < 0.01 when compared with the respective control groups.  
